Spin-out companies

A number of 'spin-out' companies have been created with the University by researchers in our school. Their aim is to investigate the possibilities of new treatments being developed in light of research discoveries that have taken place within our laboratories. Other research has lead to the development of new diagnostic techniques for patients.

Our theme in Cellular and Molecular Medicine is "Turning Science into Medicine" and it is through these spin-out companies, often working in partnership with Biotechnology companies, that we aim to make that happen. We use our know-how and expertise and the cutting-edge research that is taking place within CMM to develop therapeutics for the commercial market towards the benefit of patients in the future. It can take many years for a potential therapeutic treatment to be developed, from first discoveries in the laboratory, through testing and development, until it finally reaches the patient. Current projects include investigating the use of adult stem-cells to repair damage to torn joint tissue; treat chronic conditions such as multiple sclerosis and vaccine development.

Apitope

Principal investigator: Professor David Wraith

Apitope Technology (Bristol) Ltd (Apitope, the Company) is a biopharmaceutical company with world leading research and development in the treatment of allergy and autoimmune diseases. Apitope is developing novel therapeutic peptide vaccines that represent major advances in therapy and address critical unmet needs. Apitope has an impressive record of commercial and technical achievement since its founding at the University of Bristol in 2002 and has built an exciting and innovative product portfolio.

Apitope was a national runner-up in the UK Trade and Investment 'BioEntrepreneurial Company of the Year' awards.

Apitope Technology Ltd aims to revolutionise treatment of chronic autoimmune and allergic disorders. The company has patented technology allowing the design of safe and effective peptide therapeutics (Apitopes) for these diseases. The company will design, produce and test the safety and efficacy of Apitopes initially in multiple sclerosis and type 1 diabetes, and later in other common chronic diseases.

Azellon Cell Therapeutics

Principal investigator: Professor Anthony Hollander

Azellon is a spin-out company from The University of Bristol focused on the research, development and commercialisation of an adult autologous (patient's own) stem cell technology which in vitro (tissue culture) has shown great promise for the healing of meniscal tears.

With £1.6 million in seed funding Azellon has until mid 2011 to take the technology from in vitro promise to its first trial in patients.

KWS BioTest

Principal investigator: Professor Neil Williams

KWS BioTest Ltd is a contract research organisation specialising in drug efficacy trials for immune diseases. The company has a range of models for immune and infectious diseases and will work closely with clients to design and implement cost-effective pre-clinical pharmacology programs to test the efficacy of lead compounds and to define suitable markers for clinical development. KWS has signed a sales and marketing agreement with BioDynamics Research Ltd. BioDynamics will promote KWS' services to its growing list of customers in Europe and Japan.

Hunter Fleming Ltd (Aegis)

Principal investigator: Professor Neil Williams

Hunter-Fleming acquired spin-out company Aegis Pharmaceuticals to focus on an exciting novel treatment for asthma and auto-immune disorders from the University of Bristol.

Aegis Pharmaceuticals Ltd. was a University of Bristol spin out company set up in December 1999 to develop novel pharmaceutical products for the treatment of immunological and infectious disease. Drug discovery company Hunter-Fleming acquired Aegis and merged the company into Hunter-Fleming at the beginning of 2001. The Aegis technology is based on the development of a bacterial protein for correcting disorders of the immune system such as diabetes, rheumatoid arthritis and allergic rhinitis; and for improving the effectiveness of vaccines used to combat bacterial and viral infections. Hunter-Fleming has recently completed a £15.5 million funding round for continued development of its portfolio of technologies. This exercise also involved the formulation of new company, Trident Pharmaceuticals plc.